Qbiotics, page-124

  1. 2,443 Posts.
    21 September 2020

    The US Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) has concluded that all technical sections for the STELFONTA (tigilanol tiglate) application for marketing authorisation are complete. The final stage of administrative review has commenced, with formal registration as a veterinary pharmaceutical expected mid-November 2020 pending approval.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.